Header Logo

Connection

AMY B HEIMBERGER to Brain Neoplasms

Back to Details
This is a "connection" page, showing publications AMY B HEIMBERGER has written about Brain Neoplasms.
AMY B HEIMBERGER
Connection Strength
10.463
Brain Neoplasms
  1. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 06 01; 11(2):CNS87.
    View in: PubMed
    Score: 0.256
  2. New Approaches to Glioblastoma. Annu Rev Med. 2022 01 27; 73:279-292.
    View in: PubMed
    Score: 0.246
  3. Intratumoral Delivery of STING Agonist Results in Clinical Responses in Canine Glioblastoma. Clin Cancer Res. 2021 10 15; 27(20):5528-5535.
    View in: PubMed
    Score: 0.244
  4. Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy. Cells. 2021 08 09; 10(8).
    View in: PubMed
    Score: 0.243
  5. Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight. 2020 09 03; 5(17).
    View in: PubMed
    Score: 0.228
  6. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clin Cancer Res. 2020 09 15; 26(18):4983-4994.
    View in: PubMed
    Score: 0.225
  7. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clin Cancer Res. 2020 09 01; 26(17):4699-4712.
    View in: PubMed
    Score: 0.225
  8. Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications. Neuro Oncol. 2020 02 20; 22(2):180-194.
    View in: PubMed
    Score: 0.220
  9. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019 01 02; 129(1):137-149.
    View in: PubMed
    Score: 0.201
  10. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer. 2018 12 01; 143(11):3019-3026.
    View in: PubMed
    Score: 0.200
  11. Comment on "Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma". Neuro Oncol. 2018 06 18; 20(7):1003-1004.
    View in: PubMed
    Score: 0.195
  12. Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol. 2018 06 01; 77(6):437-442.
    View in: PubMed
    Score: 0.195
  13. Tumor Vaccines for Malignant Gliomas. Neurotherapeutics. 2017 04; 14(2):345-357.
    View in: PubMed
    Score: 0.180
  14. Immune modulatory nanoparticle therapeutics for intracerebral glioma. Neuro Oncol. 2017 03 01; 19(3):372-382.
    View in: PubMed
    Score: 0.179
  15. GBM-associated mutations and altered protein expression are more common in young patients. Oncotarget. 2016 Oct 25; 7(43):69466-69478.
    View in: PubMed
    Score: 0.174
  16. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66.
    View in: PubMed
    Score: 0.171
  17. Immunotherapy in glioblastoma: emerging options in precision medicine. CNS Oncol. 2016 07; 5(3):175-86.
    View in: PubMed
    Score: 0.169
  18. Principles of immunotherapy. Handb Clin Neurol. 2016; 134:163-81.
    View in: PubMed
    Score: 0.165
  19. Cytomegalovirus-targeted immunotherapy and glioblastoma: hype or hope? Immunotherapy. 2016; 8(4):413-23.
    View in: PubMed
    Score: 0.165
  20. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2016 05; 18(5):639-48.
    View in: PubMed
    Score: 0.164
  21. Immunosuppressive mechanisms in glioblastoma. Neuro Oncol. 2015 Nov; 17 Suppl 7:vii9-vii14.
    View in: PubMed
    Score: 0.163
  22. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016 Feb; 18(2):195-205.
    View in: PubMed
    Score: 0.161
  23. The role of STAT3 in tumor-mediated immune suppression. J Neurooncol. 2015 Jul; 123(3):385-94.
    View in: PubMed
    Score: 0.155
  24. Therapeutic targets in subependymoma. J Neuroimmunol. 2014 Dec 15; 277(1-2):168-75.
    View in: PubMed
    Score: 0.152
  25. Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J Natl Cancer Inst. 2014 Aug; 106(8).
    View in: PubMed
    Score: 0.148
  26. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol Res. 2013 Aug; 1(2):112-22.
    View in: PubMed
    Score: 0.139
  27. The controversial role of microglia in malignant gliomas. Clin Dev Immunol. 2013; 2013:285246.
    View in: PubMed
    Score: 0.139
  28. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 2013 Jul 01; 73(13):3913-26.
    View in: PubMed
    Score: 0.137
  29. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget. 2012 Sep; 3(9):1036-48.
    View in: PubMed
    Score: 0.131
  30. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. 2012 Jul 01; 131(1):8-17.
    View in: PubMed
    Score: 0.122
  31. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin Cancer Res. 2011 Jul 15; 17(14):4642-9.
    View in: PubMed
    Score: 0.119
  32. Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma? Neuro Oncol. 2011 Jan; 13(1):3-13.
    View in: PubMed
    Score: 0.116
  33. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 2011 Mar; 13(3):324-33.
    View in: PubMed
    Score: 0.116
  34. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res. 2010 Dec 01; 16(23):5722-33.
    View in: PubMed
    Score: 0.115
  35. Immune therapeutic targeting of glioma cancer stem cells. Target Oncol. 2010 Sep; 5(3):217-27.
    View in: PubMed
    Score: 0.114
  36. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010 Nov; 12(11):1113-25.
    View in: PubMed
    Score: 0.113
  37. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res. 2010 Jan 15; 16(2):461-73.
    View in: PubMed
    Score: 0.109
  38. yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med. 2009 Nov 09; 7:92.
    View in: PubMed
    Score: 0.108
  39. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. Expert Opin Biol Ther. 2009 Aug; 9(8):1087-98.
    View in: PubMed
    Score: 0.106
  40. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin Neurosurg. 2009; 56:98-106.
    View in: PubMed
    Score: 0.101
  41. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008 Dec 15; 14(24):8228-35.
    View in: PubMed
    Score: 0.101
  42. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2009 Jul; 58(7):1023-32.
    View in: PubMed
    Score: 0.100
  43. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008 Sep 15; 14(18):5759-68.
    View in: PubMed
    Score: 0.099
  44. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008 Aug 15; 14(16):5166-72.
    View in: PubMed
    Score: 0.099
  45. Topotecan enhances immune clearance of gliomas. Cancer Immunol Immunother. 2009 Feb; 58(2):259-70.
    View in: PubMed
    Score: 0.098
  46. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study. Neuro Oncol. 2008 Feb; 10(1):98-103.
    View in: PubMed
    Score: 0.094
  47. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007 Oct 15; 67(20):9630-6.
    View in: PubMed
    Score: 0.093
  48. Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res. 2007 Jun 15; 13(12):3559-67.
    View in: PubMed
    Score: 0.091
  49. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008 Jan; 57(1):123-31.
    View in: PubMed
    Score: 0.091
  50. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006 Jul; 8(3):261-79.
    View in: PubMed
    Score: 0.085
  51. Immunotherapy for human glioma: innovative approaches and recent results. Expert Rev Anticancer Ther. 2005 Oct; 5(5):777-90.
    View in: PubMed
    Score: 0.081
  52. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res. 2005 Jan 01; 11(1):267-72.
    View in: PubMed
    Score: 0.077
  53. Multimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy. Proc Natl Acad Sci U S A. 2024 Feb 20; 121(8):e2306973121.
    View in: PubMed
    Score: 0.072
  54. Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases. J Clin Invest. 2023 Dec 15; 133(24).
    View in: PubMed
    Score: 0.071
  55. Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results. Acta Neuropathol Commun. 2023 11 02; 11(1):175.
    View in: PubMed
    Score: 0.071
  56. Postoperative risk of IDH-mutant glioma-associated seizures and their potential management with IDH-mutant inhibitors. J Clin Invest. 2023 06 15; 133(12).
    View in: PubMed
    Score: 0.069
  57. Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment. Mol Cancer Res. 2023 05 01; 21(5):389-396.
    View in: PubMed
    Score: 0.068
  58. Determining venous thromboembolism risk in patients with adult-type diffuse glioma. Blood. 2023 03 16; 141(11):1322-1336.
    View in: PubMed
    Score: 0.068
  59. Circadian regulator CLOCK promotes tumor angiogenesis in glioblastoma. Cell Rep. 2023 02 28; 42(2):112127.
    View in: PubMed
    Score: 0.067
  60. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J Clin Invest. 2023 01 03; 133(1).
    View in: PubMed
    Score: 0.067
  61. CXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma. Int J Cancer. 2023 02 15; 152(4):713-724.
    View in: PubMed
    Score: 0.066
  62. Fibrinogen-like protein 2: Its biological function across cell types and the potential to serve as an immunotherapy target for brain tumors. Cytokine Growth Factor Rev. 2023 02; 69:73-79.
    View in: PubMed
    Score: 0.065
  63. Circadian Regulator CLOCK Drives Immunosuppression in Glioblastoma. Cancer Immunol Res. 2022 06 03; 10(6):770-784.
    View in: PubMed
    Score: 0.064
  64. Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma. Trends Cancer. 2022 10; 8(10):839-854.
    View in: PubMed
    Score: 0.064
  65. Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. JCI Insight. 2022 05 09; 7(9).
    View in: PubMed
    Score: 0.064
  66. A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-8.
    View in: PubMed
    Score: 0.064
  67. Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clin Cancer Res. 2022 02 15; 28(4):585-593.
    View in: PubMed
    Score: 0.063
  68. A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma. Neuro Oncol. 2021 08 02; 23(8):1337-1347.
    View in: PubMed
    Score: 0.061
  69. Opening of the Blood-Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models. Clin Cancer Res. 2021 08 01; 27(15):4325-4337.
    View in: PubMed
    Score: 0.060
  70. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375.
    View in: PubMed
    Score: 0.059
  71. FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells. Cancer Lett. 2021 05 28; 506:83-94.
    View in: PubMed
    Score: 0.059
  72. Context-Dependent Glioblastoma-Macrophage/Microglia Symbiosis and Associated Mechanisms. Trends Immunol. 2021 04; 42(4):280-292.
    View in: PubMed
    Score: 0.059
  73. Regulation of tumor immune suppression and cancer cell survival by CXCL1/2 elevation in glioblastoma multiforme. Sci Adv. 2021 01; 7(5).
    View in: PubMed
    Score: 0.059
  74. Targeting the Tumor Microenvironment in Brain Metastasis. Neurosurg Clin N Am. 2020 Oct; 31(4):641-649.
    View in: PubMed
    Score: 0.057
  75. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. EMBO J. 2020 08 03; 39(15):e103790.
    View in: PubMed
    Score: 0.056
  76. CD8+ T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas. Clin Cancer Res. 2020 08 15; 26(16):4390-4401.
    View in: PubMed
    Score: 0.056
  77. Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Cancer Cell. 2020 02 10; 37(2):243-257.e7.
    View in: PubMed
    Score: 0.055
  78. Perilesional Resection of Glioblastoma Is Independently Associated With Improved Outcomes. Neurosurgery. 2020 01 01; 86(1):112-121.
    View in: PubMed
    Score: 0.054
  79. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat Med. 2020 01; 26(1):39-46.
    View in: PubMed
    Score: 0.054
  80. Fibrinogen-like protein 2: a potential molecular target for glioblastoma treatment. Expert Opin Ther Targets. 2019 08; 23(8):647-649.
    View in: PubMed
    Score: 0.052
  81. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat Commun. 2019 01 25; 10(1):448.
    View in: PubMed
    Score: 0.051
  82. Cell surface vimentin-targeted monoclonal antibody 86C increases sensitivity to temozolomide in glioma stem cells. Cancer Lett. 2018 10 01; 433:176-185.
    View in: PubMed
    Score: 0.049
  83. Identification of metabolites in plasma for predicting survival in glioblastoma. Mol Carcinog. 2018 08; 57(8):1078-1084.
    View in: PubMed
    Score: 0.048
  84. Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. Mol Carcinog. 2018 Jan; 57(1):137-141.
    View in: PubMed
    Score: 0.047
  85. Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. J Neurooncol. 2018 Jan; 136(1):33-39.
    View in: PubMed
    Score: 0.046
  86. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048.
    View in: PubMed
    Score: 0.046
  87. Immune Checkpoint Inhibitors for Brain Metastases. Curr Oncol Rep. 2017 Jun; 19(6):38.
    View in: PubMed
    Score: 0.045
  88. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat Genet. 2017 01; 49(1):75-86.
    View in: PubMed
    Score: 0.044
  89. Interrogating Metabolism in Brain Cancer. Magn Reson Imaging Clin N Am. 2016 Nov; 24(4):687-703.
    View in: PubMed
    Score: 0.044
  90. miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis. Cancer Res. 2016 07 15; 76(14):4293-304.
    View in: PubMed
    Score: 0.042
  91. Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes. Oncotarget. 2016 Apr 12; 7(15):20486-95.
    View in: PubMed
    Score: 0.042
  92. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. J Natl Cancer Inst. 2015 Aug; 107(8).
    View in: PubMed
    Score: 0.039
  93. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015 Jun; 17(6):854-61.
    View in: PubMed
    Score: 0.039
  94. Immunotherapy for primary brain tumors: no longer a matter of privilege. Clin Cancer Res. 2014 Nov 15; 20(22):5620-9.
    View in: PubMed
    Score: 0.038
  95. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. J Neurosurg. 2013 Apr; 118(4):873-883.
    View in: PubMed
    Score: 0.034
  96. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012 Mar; 14(3):246-55.
    View in: PubMed
    Score: 0.031
  97. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery. 2012 Jan; 70(1):234-43; discussion 243-4.
    View in: PubMed
    Score: 0.031
  98. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010 Nov 01; 28(31):4722-9.
    View in: PubMed
    Score: 0.029
  99. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010 May 01; 16(9):2550-61.
    View in: PubMed
    Score: 0.028
  100. Clinical applications of a peptide-based vaccine for glioblastoma. Neurosurg Clin N Am. 2010 Jan; 21(1):95-109.
    View in: PubMed
    Score: 0.027
  101. The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am. 2010 Jan; 21(1):125-37.
    View in: PubMed
    Score: 0.027
  102. EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol. 2009 Oct; 19(4):713-23.
    View in: PubMed
    Score: 0.027
  103. IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the temozolomide era. Int J Cancer. 2009 Aug 01; 125(3):680-7.
    View in: PubMed
    Score: 0.026
  104. Awake craniotomy for brain tumors near eloquent cortex: correlation of intraoperative cortical mapping with neurological outcomes in 309 consecutive patients. Neurosurgery. 2009 May; 64(5):836-45; discussion 345-6.
    View in: PubMed
    Score: 0.026
  105. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol. 2008 Oct; 20(5):267-75.
    View in: PubMed
    Score: 0.024
  106. The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia. Int J Mol Sci. 2021 Dec 13; 22(24).
    View in: PubMed
    Score: 0.016
  107. Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling. BMC Neurol. 2021 Jun 23; 21(1):231.
    View in: PubMed
    Score: 0.015
  108. Blood-brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors. J Neurooncol. 2021 Jan; 151(1):65-73.
    View in: PubMed
    Score: 0.014
  109. Epidermal growth factor receptor and variant III targeted immunotherapy. Neuro Oncol. 2014 Oct; 16 Suppl 8:viii20-5.
    View in: PubMed
    Score: 0.009
  110. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012 Sep; 14(9):1136-45.
    View in: PubMed
    Score: 0.008
  111. Modulation of angiogenic and inflammatory response in glioblastoma by hypoxia. PLoS One. 2009 Jun 17; 4(6):e5947.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.